IL15 and lymphoid neoplasm: Our results suggest that drugs blocking translation, IL-15, JAK or mTOR downstream of this cytokine might concur in the treatment of lymphoid tumors of NK cell origin depending on MYC (Devlin et al, 2016; Schwartz et al, 2017; Laham-Karam et al, 2020).